Exploring KEAP1 Mutations and Hereditary Kidney Cancer Susceptibility
Official title: Investigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell Carcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-11381070 · Data updated 2026-11-12
This grant supports a clinician-scientist in studying how KEAP1 gene changes may increase the risk of hereditary kidney cancer and what this means for screening and targeted treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $266,666 |
| NIH project number | 5K08CA272960-04 |
| Project ID | NIH-11381070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with hereditary RCC or RCC with KEAP1 mutations who may participate in genetic analysis, biomarker studies, or related translational research.
✕Less likely to help
Patients without access to study sites or without KEAP1-related RCC may not directly benefit.
What this research studies
A physician-scientist at MSK is building a translational program to understand how KEAP1 germline and somatic mutations influence renal cell carcinoma. The project will combine genetic epidemiology, bioinformatics, and cancer modeling to define the RCC phenotype associated with KEAP1 alterations. The aim is to create a pathway from discovery to practical implications for screening and personalized therapies in patients with hereditary RCC. Training and mentorship are emphasized to enable the investigator to lead future genomic discovery studies in RCC.
Why it matters
Potential benefit: If successful, this work could lead to better screening strategies and more tailored treatments for people with hereditary forms of RCC.
How similar studies have gone: Previous work in KEAP1 and RCC suggests a potential link, but translational pathways to screening and treatment are still developing.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Carlo, Maria — Sloan-Kettering Inst Can Research
- Study coordinator: Carlo, Maria
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.